Athersys (NASDAQ:ATHX) is up 26% premarket on light volume in reaction to its announcement that
the FDA has signed off on a pivotal Phase 2/3 clinical trial, MACOVIA,
evaluating MultiStem therapy in COVID-19 patients with
moderate-to-severe acute respiratory distress syndrome, a Fast
Track-tagged indication.
The primary endpoint of the open-label study will
be the number of ventilator-free days compared to placebo. Secondary
endpoints will include pulmonary function, all-cause mortality,
tolerability and quality of life measures. The study will launch this
quarter.
https://seekingalpha.com/news/3560018-athersys-on-go-pivotal-study-of-multistem-in-covidminus-19-shares-up-26-premarket
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.